the year in diabetes 2013-2014 guillermo umpierrez, md, cde emory university atlanta, ga
TRANSCRIPT
The Year in Diabetes2013-2014
Guillermo Umpierrez, MD, CDEEmory University
Atlanta, GA
Outline• Clinical Care
– Individualization of Goals– Medications– Hypoglycemia
• Technology– Low glucose suspend– Outpatient artificial pancreas studies– Bi-hormonal artificial pancreas
• Epidemiology– Look AHEAD
Diabetes Care 35: 1364-1379, 2012
T2DM Anti-hyperglycemic Therapy: General Recommendations Diabetes Care 2012;35:1364–1379Diabetologia 2012;55:1577–1596
SU TZD DPP-4 GLP-1 Insul
Met
SU +TZD
+DPP4
+GLP1
+Insulin
+
Insulin(multiple daily doses)
Insulin
Diabetes Care, Diabetologia. 19 April 2012 [Epub ahead of print](Adapted with permission from: Ismail-Beigi F, et al. Ann Intern Med 2011;154:554)
7%
Diabetes Care 2012;35:1364–1379Diabetologia 2012;55:1577–1596
Patient characteristics that influence judgement for treatment of hyperglycemia.
Diabetes Care 2012;35:1364–1379Diabetologia 2012;55:1577–1596
Figure 1 Diabetes Care 2012;35:1364–1379Diabetologia 2012;55:1577–1596
Garber et al. Endocrine Practice, in press 2013
Turner LW Diabetes Care epub 22 NOV 2013
SGLT-2 Inhibitor – kidney is target organRenal glucose reabsorption
Glucose
Proximal tubule
S1 segment
SGLT2~90%
glucose reabsorption
SGLT-1~10%
glucose reabsorption
S3 segment
Collectingducts
SGLT-2 Inhibitor – Mechanism of Action
Glucose
SGLT-2Inhibitor
s
Glucosuria Loss of calories
Stenlöf et al, Diabetes Obes Metab. 2012 Dec 26. [Epub ahead of print]
Canagliflozin monotherapy vs Placebo in Patients with T2D
Stenlöf et al, Diabetes Obes Metab. 2012 Dec 26. [Epub ahead of print]
Canagliflozin monotherapy vs Placebo in Patients with T2D
Weight Change
Meta-analysis for HbA1c change from baseline, 10 mg dapagliflozin versus placebo
Clar et al, BMJ 2 (5): 1-7, 2012
Perspectives on SGLT2 Inhibition
• Concerns– Polyuria– Electrolyte disturbances– Bacterial urinary tract
infections– Fungal genital infections– Malignancies
• Advantages– Improved glycemic
control– Weight loss (75g urine
glucose = 300kcal/day)– Low risk of hypoglycemia– Blood pressure
lowering?
GLP1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus
Singh et al. JAMA Intern Med. 2013;173(7):534-539
Design: Population-based case-control study.
Setting: A large administrative database in the U.S.
Results: Adjusted risk (including metformin therapy), current use of GLP-1–based therapies within 30 days (OR 2.24 [95% CI, 1.36-3.68]) and past use >30 days and < 2 years (2.01 [1.37-3.18]) relative to the odds in nonusers.
Pancreatitis and Exenatide
• 30 cases of exenatide associated pancreatitis via FDA AERS.
• Onset of symptoms from 3-400 days after drug initiation.
• Resolution of symptoms concurrent with stopping exenatide in 22/30
• Recurrent symptoms in 3 patients restarted on drug• 27/30 patients had another risk factor for
pancreatitis- obesity, hyperlipidemia, ETOH
Ahmad, S New Eng J Med 358: 1970-1971, 2008
Database Studies
M Elashoff, Gastroenterology, 2010S Singh, JAMA Internal Med, 2013
D Dore, Curr Med Res Op, 2009R Garg, Diabetes Care, 2010D Dore, DOM, 2011
Pancreatic glucagon expressing neuroendocrine tumor and microadenoma.
Butler et al, Diabetes, 2013
~40% increased pancreatic mass in DM treated with incretin therapy with both increased exocrine cell proliferation (p<0.0001) and dysplasia (increased pancreatic intraepithelia neoplasia, p<0.01).
α cell hyperplasia and glucagon expressing microadenomas (3/8) and a neuroendocrine tumor.
Preclinical studiesStudies demonstrating histopathology
Studies demonstrating no histopathology
JS Nachnani, Diabetologia, 2010AV Matveyenko, Diabetes, 2009B Gier, Diabetes 2012
J Koeleher, Diabetes, 2009K Tatarkiewicz, AJP, 2010N Nyborg, Diabetes 2012K Tatarkiewicz, DOM, 2013K Aston-Mourney, AJP, 2013
Non-Matching Cohorts in Autopsy Study from Butler (Diabetes 62:2595-2604, 2013)
Harja E et al Diab Tech Ther 15: July 2013 epub DOI: 10.1089/dia.2013.0177
Staining Specificity of GLP-1R Antibodies
Pyke C et al: Endocrinology 154:4-8; 2013
Monoclonal ab3F52
Polyclonal abAB39072
Polyclonal abLS-A1205
Polyclonal abAP23801
Non-transfectedBHK cells
GLP-1RtransfectedBHK cells
Endocrine Society Statement - 6/18/2013
• Patients should be made aware of this potential side effect of incretins and the symptoms of pancreatitis.
• Providers should balance risk and benefit of particular treatment paradigms, especially in patients with other risk factors for pancreatitis.
• Patients should not stop medications on their own without consulting their health care provider.
• Manufacturers should make the data on rates of pancreatitis and pancreatic cancer available to an independent scientists for analysis.
Incretin Agents
FDA Postmarket Drug Safety Information for Patients and ...www.fda.gov/Drugs/DrugSafety/Postmarketdrugsafe
Cardiovascular Outcome Studies with DPP-4i and GLP-1RA
Kahn SE, Diabetes 62: 2178-2180, 2013
Cardiovascular Outcome Studies with DPP-4i and GLP-1RA
Kahn SE, Diabetes 62: 2178-2180, 2013
increased rate of hospitalization for heart failure
Outline• Clinical Care
– Individualization of Goals– Medications
–Hypoglycemia• Technology
– Low glucose suspend– Outpatient artificial pancreas studies– Bi-hormonal artificial pancreas
• Epidemiology– Look AHEAD
J Clin Endo Metab April 15, 2013 doi: 10.2337/dc12-2480
New Categories of Hypoglycemia
1) Severe hypoglycemia:– requiring assistance of another person.
2) Documented symptomatic hypoglycemia:– typical symptoms of hypoglycemia are accompanied by glucose
concentration ≤70 mg/dL
3) Asymptomatic hypoglycemia: – No symptoms but with glucose concentration ≤ 70 mg/dL
4) Probable symptomatic hypoglycemia:– Symptoms of hypoglycemia are not accompanied by glucose measure
5) Pseudo-hypoglycemia: – symptoms of hypoglycemia with a measured glucose >70 mg/dL
Diabetes Care 36:3535–3542, 2013
Diabetes Care 36:3535–3542, 2013
JCEM epub ahead of print Jan 10, 2014
Outline• Clinical Care
– Individualization of Goals– Medications– Ischemic preconditioning– Hypoglycemia
• Technology
–Low glucose suspend– Outpatient artificial pancreas studies– Bi-hormonal artificial pancreas
• Epidemiology– Look AHEAD
• Two New Hormones– Irisin– Betatrophin
Veo* Insulin Pump
Linked Meter
MiniLink Sof-Sensor®
CareLink USB®™
Low Alerts: Hypoglycemia,Predictive, Suspend
N Engl J Med 369:224-32, 2013
N Engl J Med 368:824-33, 2013
Outline• Clinical Care
– Individualization of Goals– Medications– Ischemic preconditioning– Hypoglycemia
• Technology– Low glucose suspend– Outpatient artificial pancreas studies
–Bi-hormonal artificial pancreas• Epidemiology
– Look AHEAD
CMAJ 2013, 185: 297-205
Diabetes Care 35:2148–2155, 2012
Outline• Clinical Care
– Individualization of Goals– Medications– Ischemic preconditioning– Hypoglycemia
• Technology– Low glucose suspend– Outpatient artificial pancreas studies– Bi-hormonal artificial pancreas
• Epidemiology
–Look AHEAD
N Engl J Med Published June 24, 2013. DOI: 10.1056/NEJMoa1212914
Design
• 16 U.S. study centers - 5145 overweight or obese DM type 2 randomized to:– an intensive lifestyle intervention that promoted
weight loss through decreased caloric intake and increased physical activity (intervention group)
Or – diabetes support and education (control group)
• The primary outcome was a composite of death from CV causes, nonfatal MI, nonfatal stroke, or hospitalization for angina during a maximum follow-up of 13.5 years.
Outline• Clinical Care
– Individualization of Goals– Medications– Ischemic preconditioning– Hypoglycemia
• Technology– Low glucose suspend– Outpatient artificial pancreas studies– Bi-hormonal artificial pancreas
• Epidemiology– Look AHEAD
THANK YOU